HC Wainwright Has Lowered Expectations for Savara (NASDAQ:SVRA) Stock Price

Savara (NASDAQ:SVRA) had its target price reduced by investment analysts at HC Wainwright from $10.00 to $6.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 69.01% from the company’s previous close.

A number of other equities analysts have also commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Price Performance

Shares of SVRA traded down $0.28 during mid-day trading on Wednesday, reaching $3.55. 497,604 shares of the company’s stock were exchanged, compared to its average volume of 1,199,064. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The company has a 50-day simple moving average of $3.97 and a two-hundred day simple moving average of $4.22. Savara has a 52-week low of $3.28 and a 52-week high of $5.70. The company has a market cap of $584.33 million, a price-to-earnings ratio of -8.45 and a beta of 1.02.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, sell-side analysts predict that Savara will post -0.44 EPS for the current fiscal year.

Institutional Trading of Savara

A number of institutional investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co acquired a new stake in Savara during the first quarter valued at approximately $35,000. Choreo LLC acquired a new stake in shares of Savara during the second quarter valued at approximately $59,000. DRW Securities LLC acquired a new stake in shares of Savara during the second quarter valued at approximately $62,000. Principal Financial Group Inc. raised its holdings in shares of Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Finally, Profund Advisors LLC acquired a new stake in shares of Savara during the second quarter valued at approximately $105,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.